Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | Current and upcoming CAR-T’s for large B-cell lymphoma

Frederick Locke • 2 Jun 2019
ASCO 2019
B-Cell Lymphoma Lymphoma Axicabtagene ciloleucel Tisagenlecleucel
JULIET TRANSCEND-NHL-001 ZUMA-1

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the CAR T-cell therapies available for the treatment of large B-cell lymphoma, and also what is to come for CAR-T treatments for this indication. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US
1:32
The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US
Frederick Locke • 7 Dec 2025
Immune exhaustion impacts CAR T-cell efficacy in Richter’s transformation
1:18
Immune exhaustion impacts CAR T-cell efficacy in Richter’s transformation
Frederick Locke • 7 Dec 2025
Integrating autoimmune diseases into cellular therapy centers
26:06
Integrating autoimmune diseases into cellular therapy centers
Frederick Locke • 12 Apr 2025
Real-world trends of CRS and ICANS among patients receiving axi-cel for R/R LBCL: a CIBMTR Report
1:47
Real-world trends of CRS and ICANS among patients receiving axi-cel for R/R LBCL: a CIBMTR Report
Frederick Locke • 7 Dec 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Frederick Locke • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Frederick Locke • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Frederick Locke • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Frederick Locke • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals